Novel biomarkers added to movement disorders profile: Andrew McKeon, M.B., B.Ch., M.D.

(00:32) Can you tell our audience a little bit about yourself and your role here at Mayo Clinic?(01:29) Can you tell our listeners a little bit about the disease state when we talk about autoimmune or paraneoplastic movement disorders?(02:37) Are we seeing an increased prevalence of autoimmune movement disorders?(04:00) Can you give our listeners an overview of what's going to be launched here in January?(06:56) What other antibodies are particularly important in this phenotype?(10:01) How does the kelch-like protein 11 phenotype manifest in this disorder?(10:49) Are there any antibodies in the autoimmune neurology space that would not need to be evaluated for in patients that present with some sort of movement disorder? (11:18) Which patients should have this testing and when should it be performed?(12:55) When should Mayo Clinic Laboratories' stiff person evaluation and standalone glycine receptor tests be used, and in what order?(14:40) Is the movement disorder evaluation the right first choice when the patient presentation is less typical and includes ataxia?(16:42) Can physicians order the glycine receptor standalone test to fully evaluate the spectrum of antibodies?(18:39) How does the evaluation impact patient care?(20:12) Have these new antibodies been shown to be immunotherapy-responsive?(20:27) Is there a key takeaway with the launch of these new antibodies in the movement disorder evaluation?